2025
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial
Somé A, Somé A, Sougué E, Ouédraogo C, Da O, Dah S, Nikièma F, Magalhaes T, Gray L, Finical W, Pugh G, Lado P, Randall J, Burton T, Ring M, Leon A, Colt M, Li F, Wang K, Wade M, Lier A, Richards K, Sproch H, Zhang E, Ellman J, Achebe I, Jackson C, Xiao M, Wu E, Bousema T, Slater H, Foy B, Parikh S, Dabiré R. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. The Lancet Infectious Diseases 2025 PMID: 39919778, DOI: 10.1016/s1473-3099(24)00751-5.Peer-Reviewed Original ResearchSeasonal malaria chemopreventionIvermectin mass drug administrationEntomological inoculation rateMalaria incidenceParallel-group trialMass drug administrationDouble-blindPlacebo-controlledControl groupAdverse eventsPrimary outcomeWeekly active case detectionDrug AdministrationLow malaria incidenceIntervention groupReducing malaria incidenceMalaria-endemic regionsMalaria incidence ratesRisk of adverse eventsInoculation rateNational Institute of AllergyPan African Clinical Trials RegistryComplementary vector control toolsCluster-randomisedInstitute of Allergy
2020
Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis
Saito M, Mansoor R, Kennon K, Anvikar AR, Ashley EA, Chandramohan D, Cohee LM, D'Alessandro U, Genton B, Gilder ME, Juma E, Kalilani-Phiri L, Kuepfer I, Laufer MK, Lwin KM, Meshnick SR, Mosha D, Mwapasa V, Mwebaza N, Nambozi M, Ndiaye JA, Nosten F, Nyunt M, Ogutu B, Parikh S, Paw MK, Phyo AP, Pimanpanarak M, Piola P, Rijken MJ, Sriprawat K, Tagbor HK, Tarning J, Tinto H, Valéa I, Valecha N, White NJ, Wiladphaingern J, Stepniewska K, McGready R, Guérin PJ. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases 2020, 20: 943-952. PMID: 32530424, PMCID: PMC7391007, DOI: 10.1016/s1473-3099(20)30064-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyIndividual patient dataQuinine-based treatmentsUncomplicated falciparum malariaPregnant womenArtemether-lumefantrineFalciparum malariaTreatment failureOne-stage individual patient dataSystematic reviewPatient dataObservational cohort studyAcute adverse eventsClinical Trials RegistryGametocyte carriageQuinine monotherapyAsexual parasitaemiaFever clearanceAdverse eventsCohort studyParasite clearanceTreatment guidelinesTrials RegistryCombination therapyRisk factors
2019
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. The Lancet 2019, 393: 1517-1526. PMID: 30878222, PMCID: PMC6459982, DOI: 10.1016/s0140-6736(18)32321-3.Peer-Reviewed Original ResearchConceptsMass drug administrationCluster-randomised trialIntervention groupMalaria episodesControl groupDrug AdministrationDetection cohortMass administrationIvermectin mass drug administrationUncomplicated malaria episodesClinical malaria episodesMalaria transmission seasonSingle oral dosesControl of malariaAdverse eventsCumulative incidencePrimary outcomeOral dosesEligible participantsAdverse reactionsFurther dosesTwo-armExclusion criteriaTransmission seasonTreatment phase
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply